Roche Holding stock heads into investor week after 6% sales growth

Roche's investor calendar lists the Berenberg Pharma CFO Series for Monday, November 2, 2026, at 3:00 p.m. CET in Basel. The virtual event is the next scheduled investor appointment after the company's third-quarter sales update.

Roche reported group sales of CHF 46.493 billion for the first nine months of 2026, compared with CHF 45.862 billion a year earlier. At constant exchange rates, sales increased 6%, while third-quarter sales rose 7%. The figures come from Roche's release published through Roche's nine-month sales announcement.

Sales Growth Meets Pipeline Execution

The Pharmaceuticals Division generated CHF 36.212 billion in sales through September, up 7% at constant exchange rates. Roche identified continued demand for medicines including Ocrevus, Hemlibra, Vabysmo, Phesgo and Xolair as key drivers.

Diagnostics sales reached CHF 10.281 billion and increased 4% at constant exchange rates, but were unchanged in Swiss francs. Roche maintained its 2026 outlook for mid-single-digit group sales growth and high-single-digit core earnings-per-share growth at constant exchange rates, while also expecting another dividend increase in Swiss francs.

The investor event gives shareholders an opportunity to assess how management views the late-stage pipeline and the balance between pharmaceutical growth and patent-related pressure. Roche has highlighted regulatory progress for several programs, including fenebrutinib and giredestrant, but upcoming approvals and commercial execution remain important to the investment case.

Roche Holding stock traded at 437.15 euros on Lang & Schwarz at 5:03 p.m. CET on Sunday, November 1, 2026. The real-time quote of Roche Holding stock provides the latest trading indication.

Healthcare investors will also track the wider SMI market environment as conference commentary and pipeline updates shape sentiment across the sector.

More news and analyses on Roche Holding stock